The p300/CBP inhibitors suppressed fibrotic phenotypes in both in vitro human and in vivo mouse models of pulmonary fibrosis, demonstrating the effectiveness of...
AK3280 is an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated...
A study that evaluated people with IPF waiting for lung transplants found higher death rates among Black and Hispanic patients.
After the approval of JASCAYD® in the U.S. to treat patients with idiopathic pulmonary fibrosis (IPF), Boehringer Ingelheim is pursuing new research...
The researchers' analyses zeroed in on two TGF-beta-related genes, ACVRL1 and LTBP1, that appear to play central roles in IPF lung disease. Specifically, data...
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an expansion.
Expanded Therapeutic Potential: These findings position Thykamine as a promising disease-modifying candidate for pulmonary fibrosis and other fibro-inflammatory...
New pooled data from the Phase III FIBRONEER trials were recently presented at the European Respiratory Society Congress. Nerandomilast is an oral medicine...
In summary, single-cell profiling of diagnostic-stage IPF ALI cultures revealed epithelial and mesenchymal programmes defined by profibrotic basal cells, primed...
United Therapeutics now has fresh late stage data on Tyvaso sitting in a top tier journal, which represents a clear milestone for any drug developer. With the...
